Novartis agreed to a licensing and asset-sale agreement with clinical-stage biotech Arvinas that is potentially worth more than $1 billion. Arvinas on Thursday said Novartis will make an upfront payment of $150 million in exchange for an exclusive license for the development and commercialization of ARV-766. (MarketWatch

The Department of Justice filed a complaint under the False Claims Act against Regeneron Pharmaceuticals for Medicare reimbursement fraud. The Justice Department said Regeneron fraudulently inflated Medicare reimbursement rates for Eylea, an FDA-approved eye injection used to treat wet age-related macular degeneration, diabetic eye disease and other retinal diseases that impair vision. (Rockland/Westchester Journal News

Leila Bahbah, Perrigo U.S. Women’s Health Brand Lead, appeared on the MM+M Podcast’s Fast Break to talk about how the birth control medication Opill partnered with the WNBA. With women’s basketball as popular as it’s ever been, Perrigo is aligning its OTC birth control brand with the WNBA on a partnership that will elevate the awareness of Opill over the course of the next few years. (MM+M)

The Centers for Medicare and Medicaid Services estimated that Leqembi, the recently approved Alzheimer’s treatment, could cost the program billions of dollars by next year. This goes well beyond what Wall Street or even Biogen and Eisai have projected. (STAT News)  

O.J. Simpson, the Pro Football Hall of Famer who was accused of and ultimately acquitted of the 1994 murders of his ex-wife and her friend, died of prostate cancer. In February, Simpson posted a video on X, the social media platform formerly known as Twitter, denying rumors that he was in hospice care, though he did not otherwise confirm or deny reports that he was ill. (ABC News)

Click here to view yesterday’s Five things for pharma marketers to know.